Veracyte, Inc. - Common Stock (VCYT)
24.16
+0.16 (0.67%)
NASDAQ · Last Trade: Nov 6th, 6:22 PM EST
Veracyte (VCYT) Q3 2026 Earnings Call Transcriptfool.com
Decipher volume fell short as Veracyte closed a $150M deal.
Via The Motley Fool · November 5, 2026
Top Gainers and Losers: Nov. 5 Low-Priced Market Moverschartmill.com
Via Chartmill · November 5, 2026
Today's US Session: Top Stock Gainers and Loserschartmill.com
Via Chartmill · November 5, 2026
Notable Gap Movers on Nov. 5, 2026: AEHL and ZNB Gap Higher; VCYT and MNTN Gap Lowerchartmill.com
Via Chartmill · November 5, 2026
Veracyte (NASDAQ:VCYT): Affordable Growth Backed by Strong Fundamentalschartmill.com
Via Chartmill · October 13, 2026
Veracyte (NASDAQ:VCYT) Offers Affordable Growth Backed by Strong Health and Cash Flowchartmill.com
Via Chartmill · September 21, 2026
Veracyte (NASDAQ:VCYT) Shows Affordable Growth Potentialchartmill.com
Via Chartmill · August 5, 2026
Premarket Movers: Gainers and Decliners on Nov. 5, 2026chartmill.com
Via Chartmill · November 5, 2026
What Veracyte (VCYT) Said on Its Q3 Earnings Callmarketbeat.com
Veracyte (NASDAQ:VCYT) reported 15% revenue growth for the third quarter of 2026, but lowered its near-term expectations for its Decipher Prostate test after volume came in below management’s forecast. The company also outlined a preliminary 2027 outlook for mid-single-digit revenue growth as it inv
Via MarketBeat · November 5, 2026
After-Hours Market Movers: Nov. 4, 2026 Gainers and Loserschartmill.com
Via Chartmill · November 4, 2026
Veracyte Q2 Earnings Call Highlightsmarketbeat.com
Veracyte (NASDAQ:VCYT) reported second-quarter 2026 revenue growth of 15% and raised its full-year revenue outlook, while highlighting the launches of its Prosigna LDT breast cancer test and TrueMRD recurrence-monitoring test for muscle-invasive bladder cancer.
Chief Executive Officer Marc Stapley
Via MarketBeat · July 31, 2026
Veracyte (NASDAQ:VCYT) Smashes Q2 Estimates but Full-Year Guidance Disappoints, Shares Fallchartmill.com
Via Chartmill · July 30, 2026
Veracyte Inc (NASDAQ:VCYT) Shows a High Growth Momentum Breakout Setup Near Resistancechartmill.com
Via Chartmill · July 24, 2026
Veracyte Inc (NASDAQ:VCYT): A High Growth Stock With a Strong Technical Breakout Setupchartmill.com
Via Chartmill · July 21, 2026
Veracyte Inc (NASDAQ:VCYT) Fits the Affordable Growth Profilechartmill.com
Via Chartmill · July 6, 2026
A Veracyte Insider Sold 24,000 Company Shares for $1.1 Million. Here's a Deeper Look at the Transaction.fool.com
This genomic diagnostics company saw a notable insider sale, as shares have surged over 70% in the past year.
Via The Motley Fool · July 4, 2026
What to Know About This $197,000 Veracyte Insider Sale After a 120% Stock Rallyfool.com
This genomics diagnostics specialist, up over 120% in a year, reported a notable insider sale amid ongoing scheduled dispositions.
Via The Motley Fool · June 27, 2026
High Growth Momentum Breakout Setup: Veracyte Inc (NASDAQ:VCYT)chartmill.com
Via Chartmill · June 16, 2026
Why Veracyte Stock Is Skyrocketing Higher This Weekfool.com
Veracyte's first-quarter earnings were excellent, and the company's future looks bright.
Via The Motley Fool · May 8, 2026
Veracyte Inc (NASDAQ:VCYT) Smashes Q1 Estimates and Raises Full-Year Guidance, Shares Surgechartmill.com
Via Chartmill · May 5, 2026
Veracyte Inc (NASDAQ:VCYT) GARP Analysis Reveals Strong Growth at a Reasonable Pricechartmill.com
Via Chartmill · May 2, 2026
Veracyte (VCYT) Q1 2026 Earnings Transcriptfool.com
Veracyte (VCYT) Q1 2026 Earnings Transcript
Via The Motley Fool · May 5, 2026
Get insights into the top gainers and losers of Tuesday's after-hours session.chartmill.com
Via Chartmill · May 5, 2026